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Pathogenic mycobacteria, which cause multiple
diseases including tuberculosis, secrete factors
essential for disease via the ESX-1 protein export
system and are partially protected from host
defenses by their lipid-rich cell envelopes. These
pathogenic features of mycobacterial biology are
believed to act independently of each other. Key
ESX-1 components include three ATPases, and
EccA1 (Mycobacterium marinum MMAR_5443;
M. tuberculosis Rv3868) is the least characterized.
Here we show that M. marinum EccA1’s ATPase
activity is required for ESX-1-mediated protein
secretion, and surprisingly for the optimal synthesis
of mycolic acids, integral cell-envelope lipids.
Increased mycolic acid synthesis defects, observed
when an EccA1-ATPase mutant is expressed in an
eccA1-null strain, correlate with decreased in vivo
virulence and intracellular growth. These data
suggest that two mycobacterial virulence hallmarks,
ESX-1-dependent protein secretion andmycolic acid
synthesis, are critically linked via EccA1.
INTRODUCTION
Mycobacterium tuberculosis has infected one-third of all people
and kills twomillion people every year (Koul et al., 2011; Lo¨nnroth
et al., 2010). The disease burden is worsened because myco-
bacteria are becoming increasingly resistant to antibiotics.
Despite this, no new antimycobacterial antibiotic has been
brought to clinical use for almost 50 years, and many mycobac-372 Chemistry & Biology 19, 372–380, March 23, 2012 ª2012 Elsevieterial pathogenic mechanisms, which might provide novel drug
targets, are only beginning to be understood (Koul et al., 2011).
Mycobacteria are resistant to many of the bactericidal mech-
anisms of host immunity, at least in part because of their cell
envelope composed primarily of mycolic acids (Niederweis
et al., 2010). These mycolic acids are covalently attached to
underlying arabinogalactan-peptidoglycan and likely form the
inner leaflet of an asymmetric outer membrane, whose outer
leaflet is composed of diverse lipids (Hoffmann et al., 2008;
Minnikin et al., 2002; Niederweis et al., 2010). Many of these
surface-exposed lipids, such as trehalose dimycolate (TDM),
phthiocerol dimycocerosate (PDIM), and phenolic glycolipid
(PGL), are implicated in mycobacterial virulence (Chopra and
Gokhale, 2009; Minnikin et al., 2002). Moreover, even minor
mycolate structural changes have major effects on mycobacte-
rial virulence (Dubnau et al., 2000; Glickman et al., 2000; Yuan
et al., 1998). Thus, cell-wall mycolates and their associated
lipids are major factors in the ability of mycobacteria to cause
disease in metazoan hosts.
Little is known about how mycobacteria move proteins and
other macromolecules across this unusual cell envelope. An
export system, ESX-1 (Abdallah et al., 2007; Bitter et al., 2009),
is required for protein secretion critical to the virulence of patho-
genic mycobacteria including M. tuberculosis and its close
genetic relative, M. marinum (Gao et al., 2004), a natural path-
ogen of fish and frogs that causes a systemic tuberculosis-like
infection in these hosts (Cosma et al., 2003). ESX-1 is composed
largely of proteins encoded by a genetic locus that is altered or
partially deleted in closely related nonpathogenic species such
as the vaccine strain ofMycobacterium bovis, Bacillus Calmette-
Guerin, andMycobacterium microti (Abdallah et al., 2007; Lewis
et al., 2003; Pym et al., 2002). Key components of the ESX-1
protein secretion system include three ATPases: EccCa1
(M. marinum MMAR_5445; M. tuberculosis Rv3870) (ESX core
component [Ecc] Ca1) and EccCb1 (M. marinum MMAR_5446;r Ltd All rights reserved
Figure 1. EccA1’s ATPase Activity Is Needed for ESAT-6 Secretion
and Hemolytic Activity
(A) EccA1 contains an N-terminal tetratricopeptide repeat (TPR) domain and a
C-terminal ATPase domain.
(B) Wild-type and plasmid-encoded wild-type or EQ EccA1 are expressed at
similar levels. CF, culture filtrate; CL, whole-cell lysate; GroEL, a loading
control.
(C) EQ-EccA1 expression cannot restore ESAT-6 secretion. Ag85 complex is
a loading control, and 8-fold more normalized CF than CL was analyzed in the
Ag85 blot, whereas a 1:1 CF:CL ratio was analyzed in all other blots.
(D) Wild-type EccA1 complements eccA1::Tn’s hemolytic defect, but EQ-
EccA1 expression is similar to the buffer control. Averaged data are from three
independent experiments and are mean values ± SEM.
See also Figure S1.
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ESX-1 Component EccA1 Modulates Mycolate SynthesisM. tuberculosis Rv3871), which are thought to function in trans-
port of proteins across the cytosolic membrane (Abdallah et al.,
2007; Bitter et al., 2009), and EccA1 (M. marinum MMAR_5443;
M. tuberculosis Rv3868), a protein whose role in the ESX-1Chemistry & Biology 19, 3system, although essential (Gao et al., 2004), is less well charac-
terized. EccA1 contains two predicted domains, an N-terminal
tetratricopeptide repeat domain and a C-terminal AAA ATPase
domain (Figure 1A). M. tuberculosis EccA1 forms homohex-
amers like other AAA ATPase proteins and has measurable
ATPase activity (Luthra et al., 2008). However, it is unclear
whether EccA1’s ATPase activity is important for its cellular
function, which also is poorly defined. Here we show that an
ATPase-defective mutant of EccA1 unexpectedly binds several
enzymes involved in cell-envelope biogenesis and impedes
mycolic acid synthesis. Moreover, an eccA1-null M. marinum
strain expressing this mutant is attenuated in vivo and more
defective for intracellular growth in macrophages, even though
the eccA1-null strain already is defective in ESX-1-mediated
secretion. Thus, EccA1 is involved in two previously unlinked
virulence-associated pathways.
RESULTS
EccA1’s ATPase Activity Is Needed to Secrete ESAT-6
and Lyse Cells
To gain insight into EccA1’s function and to determine whether
EccA1’s ATPase activity is needed, we constructed an
M. marinum EccA1 point mutant, E398Q (EQ), that lacks the
catalytic glutamic acid in the conserved nucleotide-binding site
and is likely an ATP-locked form of EccA1 because it cannot
hydrolyze ATP (Hanson and Whiteheart, 2005; Zhang and Wig-
ley, 2008) (see Figure S1 available online). Wild-type or mutant
eccA1 was expressed in a previously characterized eccA1
transposon-disrupted mutant strain, eccA1::Tn (Gao et al.,
2004). Immunoblotting with an anti-EccA1 antibody detected
no EccA1 in eccA1::Tn cells, confirming the antibody specificity,
whereas similar levels of wild-type or mutant EccA1 were
detected in complemented strains (Figure 1B). EccA1 deficiency
inhibited secretion of ESAT-6, an archetypal ESX-1 substrate
(Abdallah et al., 2007; Gao et al., 2004), whereas expression of
wild-type EccA1 restored secretion (Figure 1C). Reconstitution
of eccA1::Tn with the EQ mutant did not, demonstrating that
EccA1’s ATPase activity is required to secrete ESAT-6. In
addition, eccA1::Tn lacked the ability to lyse red blood cells,
a property previously demonstrated to require ESX-1 (Gao
et al., 2004). This defect was complemented by wild-type
EccA1, but not by EQ EccA1 (Figure 1D). Thus, two assays of
ESX-1 function demonstrate a requirement for EccA1 ATPase
activity.
EQ EccA1 Interacts with Lipid Synthases
Studies using similar ATPase-defective mutants have identified
both functional roles where nucleotide hydrolysis is needed as
well as partner proteins preferentially binding to the ATP-bound
form of the protein of interest (Hanson and Whiteheart, 2005;
Zhang and Wigley, 2008). We therefore tested whether EQ
EccA1 interacted more strongly with some partner proteins in
order to gain insight into EccA1’s cellular role. SDS-PAGE
analyses of cytosolic complexes containing wild-type or EQ
EccA1 showed that many more proteins larger than 100 kDa
copurified with EQ EccA1 than did with wild-type EccA1 (Fig-
ure 2A). These coprecipitated proteins were identified by mass
spectrometry (Tables S1 and S2). Whereas the numbers of72–380, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 373
Figure 2. EQ EccA1 Interacts More Stably with Lipid Synthases
(A) Cytosolic complexes containing EccA1 were isolated and visualized by
SDS-PAGE and silver staining. EQ EccA1 coprecipitates more proteins larger
than 100 kDa compared to wild-type.
(B) Mass spectrometric analyses of coprecipitating proteins identified multiple
polyketide synthases as interacting better with EQ EccA1.
(C) Immunoblotting of coprecipitation reactions with specific antibodies shows
more Pks13 and Mas interacting with EQ EccA1 (left). Quantitated values from
two independent experiments are shown (right).
(D) All EccA1 variants interact with Pks131–1340, KasB, and KasA as strongly as
a control in a two-hybrid experiment, and less well with MmaA4. Percent
interaction is calculated from the ratio of colonies on selective plates to those
on nonselective plates. Averaged data are from two or more independent
experiments, and mean values ± SEM are shown.
See also Figure S2 and Tables S1 and S2.
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374 Chemistry & Biology 19, 372–380, March 23, 2012 ª2012 ElsevieEccA1-derived peptides were similar in bacterial samples
expressing either wild-type or EQ EccA1, EQ-containing com-
plexes were enriched for multiple proteins involved in mycobac-
terial lipid synthesis (Bhatt et al., 2007; Chopra and Gokhale,
2009; Minnikin et al., 2002) including Pks13, KasB, KasA,
MmaA4, Pks5, Mas, Pks15/1, PpsD, and PpsE (Figure 2B), as
detected either by total peptides isolated (top) or when normal-
ized to peptides found in the eccA1::Tn sample (bottom).
Pks13, KasB, KasA, and MmaA4 are important enzymes in the
fatty acid synthase II (FAS-II) system that makes mycolic acid
and mycolate-containing lipids such as TDM (Bhatt et al.,
2007; Dubnau et al., 2000; Takayama et al., 2005; Veyron-Chur-
let et al., 2005), whereas four of the other enzymes are polyketide
synthases that produce PDIM and/or PGL, two other surface-
exposed lipids (Chopra and Gokhale, 2009; Minnikin et al.,
2002). We did not detect evidence of interaction under these
conditions with a previously reported binding partner, EspC
(DiGiuseppe Champion et al., 2009). To verify enzyme associa-
tion with EQ EccA1, antibodies were raised against an enzyme
involved in mycolate synthesis, Pks13, and one involved in
polyketide synthesis, Mas (Figure S2A). Whereas all strains
produced similar amounts of Pks13 and Mas (Figure S2B),
immunoblotting showed more coisolation with EQ EccA1 than
with wild-type (Figure 2C, left). Normalized for the amount of
isolated EccA1, quantities of coprecipitated Pks13 and Mas
were approximately 2-fold greater with EQ than with wild-type
(Figure 2C, right).
EccA1 Interacts with Pks131–1340, KasB, KasA,
and MmaA4
To determine whether interaction between EccA1 and these
enzymes involved in mycolic acid synthesis depends on other
mycobacterial proteins, their interaction was assessed in an
Escherichia coli bacterial two-hybrid system (McLaughlin et al.,
2007). Wild-type and mutant EccA1 interact with Pks131–1340,
KasB, and KasA in this assay (Figure 2D) to the same extent
as wild-type EccA1 and PPE68 (M. marinum MMAR_5448;
M. tuberculosis Rv3873), whose interaction has been docu-
mented previously (Teutschbein et al., 2009). Interaction with
MmaA4 also occurs, but to a lesser extent (Figure 2D). All
mycobacterial proteins were expressed to a similar extent in
E. coli (Figure S2C). There was no difference in interactions
with wild-type or EQ EccA1 in E. coli, suggesting that addi-
tional mycobacterial proteins regulate these interactions inr Ltd All rights reserved
Figure 3. EccA1 and the FAS-II Mycolic Acid Synthesis System
Interact Functionally
(A) Radiolabeled and isolated mycolic acid methyl esters were resolved.
(B) Quantitation revealed mycolic acid synthesis defects in eccA1::Tn and
(eccA1::Tn)/EQ. Averaged data are from three or more independent experi-
ments, and mean values ± SEM are shown (**p% 0.03).
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KasB, KasA, and MmaA4 (Veyron-Churlet et al., 2005) regulate
binding to EccA1.
EccA1 Enhances Mycolic Acid Synthesis
Pks13’s main function is to condense together the two fatty acid
chains that comprise mycolic acids, the longer meromycolate
chain produced by FAS-II and the shorter a branch produced
by the fatty acid synthase I (FAS-I) complex (Bhatt et al., 2007;
Portevin et al., 2004; Takayama et al., 2005). KasB and KasA
are integral components of FAS-II (Veyron-Churlet et al., 2004,
2005) and help make the meromycolate chain that Pks13
condenses with the a branch (Bhatt et al., 2007; Takayama
et al., 2005), whereas MmaA4 is a methyltransferase that
modifies the meromycolate chain (Dinadayala et al., 2003;
Yuan and Barry, 1996) as it is elongated by FAS-II.
We therefore tested whether mycobacterial strains lacking
functional EccA1 have defects in mycolic acid synthesis. Three
distinct types of mycolic acids (alpha, methoxy, and keto) exist
in M. marinum (Daffe´ et al., 1991), like in M. tuberculosis (Bhatt
et al., 2007;Minnikin et al., 2002; Takayama et al., 2005). Regard-
less of EccA1 expression, all three classes of mycolic acids
incorporated radiolabeled [1-14C]-tetracosanoic acid (Figure 3A).
However, eccA1::Tn produced 30%–40% less total mycolic acid
than wild-type (Figure 3B). Wild-type EccA1 complemented
this defect, but EQ EccA1 did not (Figure 3B), demonstratingChemistry & Biology 19, 3that EccA1’s ATPase activity is necessary for optimal mycolic
acid production in M. marinum.
EQ EccA1 Sensitizes Cells to Mycolic Acid Stress
To determine the functional significance of the decreased
mycolate synthesis, we examined the response of eccA1::Tn
and (eccA1::Tn)/EQ to ethionamide, an antibiotic that inhibits
mycolic acid synthesis, by monitoring their mycolic acid produc-
tion in the presence of 0.5 mg/ml ethionamide (Figure 4A, left), an
antibiotic concentration likely below the minimum inhibitory
concentration (Heifets, 1988). Mycolic acid production was
equivalently inhibited by ethionamide in wild-type and eccA1::Tn
(Figure 4A, left). Interestingly, mycolate production was 2-fold
more inhibited in the strain expressing EQ EccA1 than in wild-
type, eccA1::Tn, or (eccA1::Tn)/WT (Figure 4A, left), suggesting
that EQ-EccA1 expression further sensitized mycobacteria to
stress affecting mycolic acid production, possibly because EQ
EccA1 sequestered some of the enzymes involved in the myco-
late synthesis pathway. Increased sensitivity to ethionamide was
demonstrated as well by ethionamide’s lower half-maximal
growth-inhibitory concentration (IC50) for the EQ-EccA1 ex-
pressing strain (Figure 4A, right). This suggests that stable
EQ-EccA1 interaction with FAS-II enzymes amplifies the defect
in mycolate synthesis induced by ethionamide, since expres-
sion of wild-type EccA1 did not increase sensitivity to the
antibiotic. Moreover, sensitization by EQ EccA1 to ethionamide
appeared specific because neither eccA1::Tn nor (eccA1::Tn)/
EQ was more sensitive to two hydrophobic antibiotics, rifampin
and erythromycin (Figure 4B). The increased resistance of
eccA1::Tn and (eccA1::Tn)/EQ to rifampin and erythromycin
compared to wild-type suggests that their decreased mycolic
acid production did not result in a simple permeability defect,
as has been reported for a kasB-null strain (Gao et al., 2003).
EQ EccA1 Decreases Virulence in Zebrafish
and Intracellular Growth in Macrophages
Protein secretion through ESX-1 is important for M. marinum
virulence (Gao et al., 2004), and both eccA1::Tn and
(eccA1::Tn)/EQ do not secrete ESAT-6 (Figure 1C). Because
(eccA1::Tn)/EQmade significantly lessmycolic acid whenmyco-
late synthesis was stressed (Figure 4A, left), we tested whether
EQ EccA1 would distinctly affectM. marinum virulence in zebra-
fish, a situation likely to require maximal mycolic acid synthesis
both for bacterial growth and to repair cell-envelope damage
from host defenses (Bhatt et al., 2007; Lacave et al., 1989;
Niederweis et al., 2010; Rachman et al., 2006; Takayama et al.,
1972). To perform these experiments, wild-type or EQ eccA1
was integrated into the chromosome at the attB site (Stover
et al., 1991) to maintain stable expression during the relatively
long time frame of the zebrafish experiments. Like plasmid-
expressed EccA1 (Figure 1B), wild-type and mutant EccA1
were expressed at equivalent levels (data not shown). Zebrafish
infectedwith wild-typeM.marinum all died by 20 days postinfec-
tion (Figure 5A). eccA1::Tn showed only a small loss of virulence
in this experiment, but a higher-infecting inoculum was used
here compared to a previous study (Gao et al., 2004). Expression
of wild-type EccA1 in eccA1::Tn restored the small loss of viru-
lence, but ATPase-defective EccA1 markedly attenuated the
eccA1::Tn strain. By the time (eccA1::Tn)/EQ-infected zebrafish72–380, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 375
Figure 4. EQ-EccA1 Expression Also Sensitizes
Cells to Ethionamide Stress
(A) Left: ethionamide inhibition of mycolic acid synthesis is
plotted. (eccA1::Tn)/EQ is most inhibited. Averaged data
are from at least four independent experiments, and mean
values ± SEM are shown (*p < 0.05; ***p % 0.01). Right:
IC50 values for growth-inhibition sensitivity to ethionamide
are shown. (eccA1::Tn)/EQ is uniquely sensitized to ethi-
onamide. Mean values ± SEM are averaged data from five
independent experiments (***p% 0.01; ****p% 0.002).
(B) IC50 values for growth-inhibition sensitivity to two
hydrophobic antibiotics, rifampin and erythromycin, are
shown. (eccA1::Tn)/EQ is similar to eccA1::Tn in being
more resistant to these antibiotics. Mean values ±SEMare
averaged data from four or more independent experi-
ments (*p < 0.05; ***p% 0.01).
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wild-type, eccA1::Tn, or (eccA1::Tn)/WT had died (Figure 5A).
To explore this in vivo result, we determined the effects of EQ
EccA1 on M. marinum growth. All strains grew similarly in 7H9376 Chemistry & Biology 19, 372–380, March 23, 2012 ª2012 Elsevier Ltd All rights rebroth (Figure 5B). eccA1::Tn showed mildly
decreased growth in primary bone marrow-
derived macrophages, a defect fully comple-
mented by expression of wild-type protein.
In contrast, expression of EQ EccA1 markedly
diminished growth of eccA1::Tn in macro-
phages (Figure 5C). Statistical analyses re-
vealed significant differences between both
eccA1::Tn and (eccA1::Tn)/EQ with wild-typeor (eccA1::Tn)/WT after 48 hr. These data demonstrate that
EQ EccA1 diminishes bacterial virulence in the absence of
wild-type EccA1, a circumstance in which ESX-1-dependent
secretion is already lost.Figure 5. EQ EccA1 Further Decreases Virulence
and Intracellular Growth
(A) An EQ-expressing integrant strain is attenuated for
zebrafish killing (****p% 0.002 compared to wild-type, log-
rank test; nR 5 for each strain).
(B) All strains grew similarly in 7H9 media.
(C) eccA1::Tn is defective for intracellular growth in
bone marrow-derived macrophages. Wild-type EccA1
complements this defect, but EQ EccA1 worsens growth.
Data are averaged from three independent experiments
(**p% 0.03; ***p% 0.01; ****p% 0.002).
served
Figure 6. A Model of EccA1’s Interaction with FAS-II Proteins
For efficient mycolic acid production, EccA1must interact with FAS-II components such as Pks13, KasB, and KasA (A–C), and release them in an ATP hydrolysis-
linked manner to the rest of FAS-II (D). (eccA1::Tn)/EQ is further sensitized to mycolic acid stress, relative to eccA1::Tn, because it has a lower amount of fully
functioning Pks13, KasB, and KasA, important in (D). EccA1’s interactions with these partner proteins are shown to be direct and exclusive here, but other
mycobacterial proteins may aid these interactions or be part of these complexes. Three ATPs (shown in red) are bound to hexameric EccA1 here, but the real
number is unknown.
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Current models suggest that the mycobacterial ESX-1 system
affects virulence through secretion of protein effectors with
host-modulatory effects. Mycobacterial cell-wall lipids also
are known to be important for virulence, but there has been
little evidence for crosstalk between these key mechanisms
of pathogenesis. Our studies suggest that EccA1, a core
component of the ESX-1 secretion system (Abdallah et al.,
2007; Bitter et al., 2009), physically associates with multiple
lipid synthases, preferentially in the ATP-bound state. Disrup-
tion of EccA1 ATPase activity creates more stable interactions
with these critical cellular enzymes. The functional importance
of these interactions is supported by the observation that
eccA1::Tn mycobacteria make less mycolic acid compared to
strains expressing wild-type EccA1. Furthermore, we suggest
that expression of ATPase-deficient EccA1 worsens mycolate
synthesis when the synthesis system is under stress, perhaps
because it sequesters enzymes required for efficient mycolate
production.
Based on this, we propose that a normal role for EccA1 is to
make mycolate synthesis more efficient, perhaps by shuttling
relevant enzymes to sites of mycolate production (Figure 6).Chemistry & Biology 19, 3This is an unexpected role for an ATPase that also has a more
expected role in ESX-1-mediated substrate transport out of the
mycobacterial cell. In this way, EccA1 ties together two of
the most important virulence mechanisms of pathogenic
mycobacteria, ESX-1-mediated secretion and synthesis of its
hydrophobic cell envelope. We speculate that the decreased
pathogenicity of anM. marinum strain expressing the EQmutant
may be due to its interference with mycolic acid synthesis,
beyond the defects found in eccA1::Tn. Whereas absence of
EccA1 appears to be sufficient to abolish ESX-1-mediated
secretion, at least of ESAT-6, CFP-10 (Gao et al., 2004), and
EspE (M.marinumMMAR_5439;M. tuberculosisRv3864) (Carls-
son et al., 2009), the ATPase-defective EccA1 further inhibits
mycolate production under conditions of bacterial stress. This
correlates with decreased pathogenesis, even when ESX-1-
mediated secretion is already absent due to loss of EccA1. It is
well known that different mutations in the esx-1 locus exhibit
varying severities in virulence loss or intracellular growth, despite
the fact that all block secretion (Abdallah et al., 2007; Gao et al.,
2004; McLaughlin et al., 2007). We speculate that other genes
in the ESX-1 locus besides EccA1 also may contribute to cell-
envelope synthesis, and thus have more than one mechanism
by which they mediate virulence.72–380, March 23, 2012 ª2012 Elsevier Ltd All rights reserved 377
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Tuberculosis is an unsolved medical problem with major
global health and economic impact that has worsened
because of the HIV epidemic. Multidrug resistance is on
the rise, making some cases of the disease almost untreat-
able. Despite this, relatively few disease-causing mecha-
nisms are understood for the causative bacterium,
M. tuberculosis, and increased understanding is needed
before new drug targets are identified and new therapies
are developed. The best-characterized mycobacterial
disease-related systems are the ESX-1 protein virulence
factor export system and the waxy cell envelope composed
largely of mycolic acids, which renders the bacteria resis-
tant to host attack. Our studies on EccA1, a protein that is
a component of the ESX-1 system, reveal that EccA1 has
an unexpected role in regulatingmycolic acid lipid synthesis
via interaction with mycolic acid biosynthetic enzymes. This
interesting link between these two key disease-causing
mechanisms indicates that EccA1 represents an ‘‘Achilles’
heel’’ affecting two pathways of mycobacterial biology that
could be an appealing drug target for future therapeutic
development.
EXPERIMENTAL PROCEDURES
DNA
eccA1 (MMAR_5443) was PCR amplified from M. marinum genomic DNA,
and an N-terminal histidine tag was added. This product was cloned into
pLYG206 (Gao et al., 2004) downstream of the hsp60 promoter to produce
pWT68. The E398Q mutation was introduced into pWT68 using overlap
extension PCR mutagenesis to produce pEQ68. In order to integrate these
eccA1 variants, we excised the genes from pWT68 and pEQ68 and ligated
them into pMV306, which is an integrative vector derived from pMV361 (Stover
et al., 1991). For protein expression, we used pET-22b (Novagen) after
removing its pelB sequence. All construct sequences were verified by DNA
sequencing.
Bacterial Strains
M. marinum strain M was used in these studies. The eccA1::Tn strain is equiv-
alent to the previously published M3 strain (Gao et al., 2004). Mycobacterial
cultures were grown in 7H9 media containing ADC supplement (BD Biosci-
ences), 0.2% glycerol, and 0.05% Tween 80. 7H10 agar plates contained
OADC supplement. DNA was introduced into mycobacteria using electro-
poration. To integrate the eccA1 variants, the different pMV306 constructs
were electroporated into eccA1::Tn M. marinum and plated on 7H10 agar
plates containing 50 mg/ml hygromycin. HygR colonies were grown in liquid
culture, and total cell lysates were screened for EccA1 production by immuno-
blotting using an anti-EccA1 antibody (see below). BL21-CodonPlus (DE3)-RP
E. coli (Stratagene) was used for protein expression and purification.
Antibodies
Rabbit polyclonal antibodies were generated against EccA1, Pks13
(MMAR_5364), and Mas (MMAR_1767), using either protein or peptide
antigens. A His-tagged EccA1 N-terminal fragment containing amino acids
1–298 was purified using Ni-NTA chromatography under denaturing condi-
tions and used to raise the anti-EccA1 antibody. The other two antibodies
were raised against unique synthetic peptides conjugated to thyroglobulin.
Peptides consisted of amino acids 1653–1670 (Pks13) or 876–889 (Mas),
and their specific reactivities were verified (Figure S2A). Immunoblotting
experiments additionally used commercial antibodies against GroEL (Enzo
Life Sciences), ESAT-6 (Thermo Fisher Scientific), the antigen 85 complex
(BEI Resources; NR-13800), lambda repressor (Agilent), and RNA polymerase
subunit a (Neoclone).378 Chemistry & Biology 19, 372–380, March 23, 2012 ª2012 ElsevieSolutions
Solution A is 100 mM HEPES-KOH (pH 7.5), 10% glycerol, 0.01% Tween 80,
and 50 mM imidazole. Solution B is 100 mM HEPES-KOH (pH 7.5), 10%
glycerol, 0.01% Tween 80, 25 mM imidazole, 150 mM KCl, and 5 mM
MgCl2. Solution C is identical to solution B except that it also contains
400 mM imidazole.
Functional Tests
Contact-dependent hemolysis assays were done as previously described
(Gao et al., 2004) with a few changes. Mid-log-phase cultures were washed
in Dulbecco’s modified Eagle’s medium without phenol red and incubated
in a 2.5:1 ratio with sheep red blood cells in a 50 ml reaction for 2 hr. Zebrafish
experiments were done with adult zebrafish (Zebrafish International Resource
Center, University of Oregon) and at least five zebrafish were infected
per tested mycobacterial strain. Mycobacteria (2 3 105) were injected intra-
peritoneally into each zebrafish and time to death was noted. Macrophage
infections were done as previously described (Gao et al., 2004) with a
multiplicity of infection of 3 using 129/SvJ bone marrow-derived macro-
phages, except that infected macrophages were lysed with 0.1% Triton
X-100 before plating. Zebrafish studies followed the ethical guidelines of
the M. marinum-zebrafish infection protocol (protocol 08-124), and macro-
phage infection studies followed a mouse bone marrow-derived macrophage
protocol (protocol TH07-0474). Both protocols received ethical approval from
the Institutional Animal Care and Use Committee at Genentech, and all work
was done in an Association for Assessment and Accreditation of Laboratory
Animal Care International-accredited facility in accordance with the Guide for
the Care and Use of Laboratory Animals (Institute for Laboratory Animal
Research, 1996).
Coprecipitation of EccA1-Containing Cytosolic Complexes and
Identification Using Mass Spectrometry
M. marinum cultures grown in 7H9 media were washed in Sauton’s minimal
media (Teknova), inoculated into 100 ml Sauton’s cultures, and grown to
mid-log phase. Cytosolic fractions were collected from harvested, lysed,
and fractionated mycobacteria as previously described (Carlsson et al.,
2009). Cytosols were diluted 2-fold with solution A to end up in solution B.
Talon affinity resin (Clontech) equilibrated in solution B was added to the
cytosols in an amount normalized to the cell pellet mass used to generate
the cytosolic fraction. Cytosolic complexes containing His-tagged EccA1
variants were batch bound to Talon resin for 90 min at 4C. Complexes were
isolated after passing the cytosols through an empty column, washing the
captured resin with ten column volumes of solution B, and eluting with five
column volumes of solution C. Eluted complexesweremixed with SDS loading
buffer, boiled, and run on 4%–20% Criterion gradient gels (Bio-Rad). After
silver staining, visible bands of interest were excised and in-gel digested
with trypsin. Extracted peptides were sequenced by liquid-chromatography-
coupled ESI tandemMS (LC-MS/MS) on an LTQ-Orbitrap instrument (Thermo
Fisher Scientific). Processed MS/MS spectra were searched against the
M. marinum nonredundant database by using MASCOT (Matrix Science) as
a search engine, and were visualized and validated using the Scaffold program
(Proteome Software).
Bacterial Two-Hybrid Experiments
Interactions between EccA1 variants, PPE68 (MMAR_5448), Pks131–1340,
KasB (MMAR_3339), KasA (MMAR_3338), and MmaA4 (MMAR_0977)
were tested using the BacterioMatch II system (Agilent). Because Pks13
(MMAR_5364) is a very large molecule that might not fold correctly in E. coli,
only the first 1,340 amino acids were used (Singh et al., 2006). EccA1 variants
were cloned into the pTRG vector, whereas the other five tested proteins were
cloned into the pBT vector. Cotransformations followed the manufacturer’s
protocol, and protein interaction percentages were determined from the ratio
of colonies on selective plates to colonies on nonselective plates. Nonselective
plates contained 25 mg/ml chloramphenicol, 12.5 mg/ml tetracycline, and
50 mM IPTG, whereas selective plates additionally contained 5 mM 3-amino-
1,2,4-triazole. To test expression of these fusion proteins by immunoblotting,
we first expressed the proteins using the manufacturer’s protocol, except we
induced expression in SOC media at 37C with 50 mM IPTG.r Ltd All rights reserved
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Early-log-phase mycobacterial cultures growing in Sauton’s minimal media
were diluted to an A600 of 0.4 in 20 ml final volumes. [1-
14C]-tetracosanoic
acid (Moravek) was added to 0.5 mCi/ml and cultures were labeled for 3 hr.
For testing mycolic acid production in the presence of ethionamide, myco-
bacteria were grown in 15 ml 7H9 cultures in 50 ml tubes for 6 hr after being
diluted to an initial A600 of 0.3. Either 0.5 mg/ml ethionamide or an equal
volume of ethanol was added to each culture, along with 0.4 mCi/ml
[1-14C]-tetracosanoic acid, at the start of the experiment. Harvested cells
were washed once in water before being resuspended in 500 ml water.
Saponification, methylation, and purification to isolate mycolic acid methyl
esters (MAMEs) followed an established protocol (Vilche`ze and Jacobs,
2007). Washed MAMEs were dried under nitrogen gas and resuspended in
dichloromethane, and equal counts were applied to analytical silica gel 60
HPTLC plates (EMD Chemicals). Plates were developed three sequential
times with 95:5 hexanes/ethyl acetate and imaged using a Typhoon
PhosphorImager (GE Healthcare), and ImageQuant TL (GE Healthcare) was
used to quantitate bands on the TLC plates.
Antibiotic Growth-Inhibition Tests
Mid- to late-log-phase mycobacterial cultures grown in 7H9 rich media were
diluted to an A600 of 0.1. Two-fold serial dilutions of mycobacteria with
ethionamide, rifampin, or erythromycin were performed and a final volume of
100 ml was dispensed into each well of a 96-well plate. The tested con-
centration ranges were 0.018–18 mg/ml (ethionamide), 0.027–28 mg/ml
(rifampin), and 0.625–640 mg/ml (erythromycin). Plates were sealed with
Parafilm and grown for 48 hr at 30C with 105 rpm shaking. A600 values
were determined using a plate reader, and IC50 values (m3) were determined
after fitting the data to the four-parameter logistic equation (Baud, 1993):
y = m1 + m2/(1 + (x/m3)m4). Here, y is the observed growth expressed as
a percentage of the maximal growth, x is the antibiotic concentration, m1 is
the minimal growth asymptotic value, m2 is the difference between the
maximal and minimal growth asymptotes, m3 is the IC50 value, and m4 is
the Hill coefficient for cooperativity.
Statistical Analyses
Statistical significance of the survival of zebrafish cohorts infected with
different mycobacterial strains was determined using the log-rank test. Other-
wise, significance was determined using one-way ANOVA testing across all
the samples analyzed in a given experiment. When calculated F values
were greater than critical F values in these analyses, Fisher’s least significant
difference post hoc tests were applied to determine pairwise significant
differences. Nonsignificant F values were found in a subset of the macro-
phage infection samples (inocula, 4 hr time point, and 24 hr time point).
Significance is denoted in the figures as *p < 0.05; **p % 0.03; ***p % 0.01;
and ****p % 0.002.
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